Specimen Requirements

Alternate Specimen Requirements

Minimum Specimen Requirements

Stability

Days Performed

Mon, Tue, Thu

Turnaround Time

6 - 9 days

Methodology

Special Info

Patient Prep: For optimal antibody detection, the recommendation is to draw the specimen before initiation of immunosuppressant medication. The reflex titer test will be performed at an additional charge when the results of this assay require further evaluation. Grossly hemolyzed, grossly lipemic and grossly icteric specimens will be rejected.

Clinical Info

Useful for diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis. Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy. Diagnosis of neuromyelitis optica (NMO). Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease. Diagnosis of ADEM. Prediction of a relapsing disease course. A positive value for myelin oligodendrocyte glycoprotein (MOG)-IgG is consistent with a neuromyelitis optica (NMO)-like phenotype, and in the setting of acute disseminated encephalomyelitis (ADEM), optic neuritis and transverse myelitis indicates an autoimmune oligodendrogliopathy with potential for relapsing course. Identification of MOG-IgG allows distinction from MS and may justify initiation of appropriate immunosuppressive therapy (not MS disease-modifying agents) at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 3 to 6 months as persistence of MOG-IgG seropositivity predicts a relapsing course. This autoantibody is not found in healthy subjects. Note of caution: (MOG)-IgG, specifically MOG-IgG1, may drop below detectable levels in setting of therapies for acute attack (IV methylprednisolone or plasmapheresis) or attack prevention (immunosuppressants).